截至9月30日，白云山股东户数10.17万，较上期增加18.85%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，白云山实现营业收入616.06亿元，同比增长4.31%；归母净利润33.10亿元，同比增长 4.78%。 分红方面，白云山A股上市后累计派现109.06亿元。近三年，累计派现43.59亿元。 机构持仓方面，截止2025年9月30日，白云山十大流通股东中，中国证券金融股份有限公司位居第四大 流通股东，持股4727.80万股，持股数量较上期不变。香港中央结算有限公司位居第五大流通股东，持 股2001.09万股，相比上期减少2043.72万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持 股1214.03万股，相比上期减少49.56万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持 股881.01万股，相比上期减少271.42万股。易方达沪深300ETF（510310）位居第十大流通股东，持股 865.06万股，相比上期减少28.60万股。 责任编辑：小浪快报 1月8日，白云山盘中下跌2.00%，截至13:32，报24.93元/股，成交9.76亿元， ...

截至9月30日，白云山股东户数10.17万，较上期增加18.85%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，白云山实现营业收入616.06亿元，同比增长4.31%；归母净利润33.10亿元，同比增长 4.78%。 分红方面，白云山A股上市后累计派现109.06亿元。近三年，累计派现43.59亿元。 机构持仓方面，截止2025年9月30日，白云山十大流通股东中，中国证券金融股份有限公司位居第四大 流通股东，持股4727.80万股，持股数量较上期不变。香港中央结算有限公司位居第五大流通股东，持 股2001.09万股，相比上期减少2043.72万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持 股1214.03万股，相比上期减少49.56万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持 股881.01万股，相比上期减少271.42万股。易方达沪深300ETF（510310）位居第十大流通股东，持股 865.06万股，相比上期减少28.60万股。 融资方面，白云山当日融资买入1.55亿元。当前融资余额10.64亿元，占流通市值的2.97%，融资余额超 过近 ...

来源：新浪证券-红岸工作室 12月23日，白云山涨0.12%，成交额2.36亿元。两融数据显示，当日白云山获融资买入额2008.77万元， 融资偿还3360.92万元，融资净买入-1352.15万元。截至12月23日，白云山融资融券余额合计9.20亿元。 融资方面，白云山当日融资买入2008.77万元。当前融资余额9.18亿元，占流通市值的2.53%，融资余额 超过近一年80%分位水平，处于高位。 融券方面，白云山12月23日融券偿还200.00股，融券卖出4.46万股，按当日收盘价计算，卖出金额 115.16万元；融券余量9.79万股，融券余额252.78万元，超过近一年80%分位水平，处于高位。 资料显示，广州白云山医药集团股份有限公司位于广东省广州市荔湾区沙面北街45号,香港金钟道89号 力宝中心第2座20楼2005室，成立日期1997年9月1日，上市日期2001年2月6日，公司主营业务涉及中西 成药、化学原料药、天然药物、生物医药、化学原料药中间体的研究开发、制造与销售;西药、中药和 医疗器械的批发、零售和进出口业务;大健康产品的研发、生产与销售;及医疗服务、健康管理、养生养 老等健康产业投资等。主营 ...

Core Viewpoint - Baiyunshan Pharmaceutical Group's stock performance shows a slight decline, with significant financing activity indicating investor interest despite the drop in share price [1][2]. Financing Activity - On November 26, Baiyunshan's stock fell by 0.42%, with a trading volume of 257 million yuan. The financing buy-in amounted to 28.26 million yuan, while financing repayment was 17.54 million yuan, resulting in a net financing buy of 10.73 million yuan [1]. - As of November 26, the total financing and securities lending balance for Baiyunshan was 864 million yuan, with the financing balance accounting for 2.37% of the circulating market value, indicating a high level compared to the past year [1]. Company Overview - Baiyunshan, established on September 1, 1997, and listed on February 6, 2001, is based in Guangzhou, China. The company specializes in the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2]. - The revenue composition for Baiyunshan includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine [2]. Financial Performance - For the period from January to September 2025, Baiyunshan reported a revenue of 61.606 billion yuan, reflecting a year-on-year growth of 4.31%. The net profit attributable to shareholders was 3.31 billion yuan, with a growth of 4.78% [2]. Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.906 billion yuan in dividends, with 4.359 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Baiyunshan include China Securities Finance Corporation, holding 47.278 million shares, and Hong Kong Central Clearing Limited, which reduced its holdings by 20.437 million shares [3].

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown a mixed performance in financing activities and stockholder dynamics, with a slight increase in revenue and net profit year-on-year, indicating stable growth in its core business segments [1][2][3] Financing Activities - On November 11, Baiyunshan's financing buy-in amounted to 21.89 million yuan, while financing repayment reached 35.18 million yuan, resulting in a net financing outflow of 13.30 million yuan [1] - The total financing and securities balance for Baiyunshan as of November 11 is 859 million yuan, with the financing balance accounting for 2.23% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, Baiyunshan repaid 1,000 shares and sold 11,000 shares on November 11, with the selling amount calculated at 301,100 yuan, and the remaining securities lending balance is 8.10 million shares [1] Company Overview - Baiyunshan Pharmaceutical Group, established on September 1, 1997, and listed on February 6, 2001, operates in various sectors including traditional Chinese medicine, chemical raw materials, and health management [2] - The company's revenue composition shows that the major commercial segment contributes 69.32%, followed by health products at 16.79%, and traditional medicine at 12.53% [2] - For the period from January to September 2025, Baiyunshan reported a revenue of 61.61 billion yuan, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, up by 4.78% [2] Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.91 billion yuan in dividends, with 4.36 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include China Securities Finance Corporation, holding 47.28 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 20.44 million shares [3] - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which have seen a decrease in their holdings compared to the previous period [3]

Core Viewpoint - Baiyunshan Pharmaceutical Group's stock performance shows a slight increase, with significant financing activities indicating high investor interest and potential volatility in the market [1][2]. Financing Activities - On October 27, Baiyunshan had a financing buy-in amount of 26.22 million yuan and a financing repayment of 30.97 million yuan, resulting in a net financing outflow of 4.76 million yuan [1]. - The total financing and securities lending balance for Baiyunshan reached 949 million yuan, with the financing balance accounting for 2.62% of the circulating market value, indicating a high level compared to the past year [1]. Securities Lending - On the same day, Baiyunshan repaid 8,000 shares in securities lending, with no shares sold, resulting in a securities lending balance of 2.25 million yuan, which is also at a high level compared to the past year [1]. Company Overview - Baiyunshan, established on September 1, 1997, and listed on February 6, 2001, operates in various sectors including traditional Chinese medicine, chemical raw materials, and health management services [2]. - The company's revenue composition includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine [2]. Financial Performance - For the first half of 2025, Baiyunshan reported a revenue of 41.84 billion yuan, reflecting a year-on-year growth of 1.93%, while the net profit attributable to shareholders was 2.52 billion yuan, showing a decrease of 1.31% [2]. Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.91 billion yuan in dividends, with 4.36 billion yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders of Baiyunshan include significant institutional investors, with Hong Kong Central Clearing Limited being the fifth largest shareholder, increasing its holdings by 9.36 million shares [3].

Core Viewpoint - On September 30, Baiyunshan's stock increased by 0.24% with a trading volume of 219 million yuan, indicating active market participation and interest in the company [1] Financing Summary - On September 30, Baiyunshan had a financing buy-in amount of 22.36 million yuan and a financing repayment of 45.28 million yuan, resulting in a net financing outflow of 22.92 million yuan [1] - As of September 30, the total financing and securities lending balance for Baiyunshan was 1.015 billion yuan, with the financing balance at 1.013 billion yuan, accounting for 2.82% of the circulating market value, which is above the 90th percentile of the past year [1] - In terms of securities lending, Baiyunshan repaid 21,200 shares and sold 500 shares on September 30, with a selling amount of 12,800 yuan, while the securities lending balance was 1.99 million yuan, exceeding the 60th percentile of the past year [1] Company Overview - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. was established on September 1, 1997, and listed on February 6, 2001, with its main business involving the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2] - The revenue composition of Baiyunshan includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine, with specific contributions from various segments [2] - As of June 30, 2025, Baiyunshan reported a revenue of 41.835 billion yuan, a year-on-year increase of 1.93%, while the net profit attributable to shareholders was 2.516 billion yuan, a decrease of 1.31% year-on-year [2] Dividend and Shareholding Information - Baiyunshan has distributed a total of 10.906 billion yuan in dividends since its A-share listing, with 4.359 billion yuan distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares, and Huatai-PB CSI 300 ETF, which also saw an increase in holdings [3]

Core Insights - Baiyunshan Pharmaceutical Group Co., Ltd. has shown a slight increase in stock price by 0.04% on September 26, with a trading volume of 1.52 billion yuan [1] - The company reported a financing buy amount of 20.29 million yuan and a financing repayment of 20.96 million yuan on the same day, resulting in a net financing outflow of 0.67 million yuan [1] - As of September 26, the total financing and securities lending balance for Baiyunshan stands at 1.052 billion yuan, indicating a high level of financing activity [1] Financing Overview - On September 26, Baiyunshan's financing buy was 20.29 million yuan, with a current financing balance of 1.049 billion yuan, representing 2.94% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] Securities Lending Activity - On the same day, Baiyunshan repaid 7,100 shares in securities lending and sold 20,000 shares, amounting to 507,600 yuan based on the closing price [1] - The remaining securities lending volume is 104,500 shares, with a balance of 2.65 million yuan, also above the 90th percentile of the past year [1] Company Profile - Baiyunshan was established on September 1, 1997, and listed on February 6, 2001, with its main business involving the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2] - The company's revenue composition includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine [2] Financial Performance - For the first half of 2025, Baiyunshan achieved a revenue of 41.835 billion yuan, reflecting a year-on-year growth of 1.93%, while the net profit attributable to shareholders decreased by 1.31% to 2.516 billion yuan [2] Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.906 billion yuan in dividends, with 4.359 billion yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares, and Huatai-PB CSI 300 ETF, which also saw an increase in holdings [3]

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown mixed financial performance with slight revenue growth but a decline in net profit, alongside significant trading activity in its stock [2][3]. Financial Performance - For the first half of 2025, Baiyunshan achieved operating revenue of 41.835 billion yuan, representing a year-on-year increase of 1.93% [2]. - The net profit attributable to shareholders was 2.516 billion yuan, reflecting a year-on-year decrease of 1.31% [2]. Stock Trading Activity - On September 5, Baiyunshan's stock price increased by 0.34%, with a trading volume of 237 million yuan [1]. - The financing buy-in amount for Baiyunshan on the same day was 28.51 million yuan, while the financing repayment was 51.72 million yuan, resulting in a net financing outflow of 23.22 million yuan [1]. - As of September 5, the total financing and securities lending balance for Baiyunshan was 974 million yuan, with the financing balance accounting for 2.61% of the circulating market value [1]. Shareholder Information - As of June 30, 2025, Baiyunshan had 85,500 shareholders, a decrease of 8.54% from the previous period [2]. - The top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares [3].

Group 1 - Baiyunshan's stock price increased by 0.45% on September 2, with a trading volume of 392 million yuan [1] - The financing buy-in amount for Baiyunshan on the same day was 52.78 million yuan, while the financing repayment was 75.43 million yuan, resulting in a net financing outflow of 22.65 million yuan [1] - As of September 2, the total financing and securities lending balance for Baiyunshan was 1 billion yuan, with the financing balance accounting for 2.65% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Baiyunshan's main business includes the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products, with major revenue sources being large commercial (69.32%), health (16.79%), and traditional medicine (12.53%) [2] - For the first half of 2025, Baiyunshan reported a revenue of 41.835 billion yuan, a year-on-year increase of 1.93%, while the net profit attributable to shareholders was 2.516 billion yuan, a decrease of 1.31% year-on-year [2] Group 3 - Baiyunshan has distributed a total of 10.256 billion yuan in dividends since its A-share listing, with 3.708 billion yuan distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders of Baiyunshan included Hong Kong Central Clearing Limited and several ETFs, with notable changes in shareholding among these entities [3]